drugset / Trial / NCT02930941

Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department

NCT02930941 ↗

Phase 4 Terminated 35 enrolled University of California, Davis
RandomizedParallel-groupQuadruple-blindTreatment

Summary

It is estimated that epistaxis results in 4.5 million emergency department visits per year throughout the United States. Due to the adverse effects of standard treatment options for epistaxis, tranexamic acid (TXA) may be considered an attractive option. In previous studies, when used with nasal packing, TXA showed faster time to control of bleeding. The goal of this study is to determine the efficacy and safety of topical intranasal TXA applied via atomizer for patients with epistaxis who present to the emergency department.

Timeline

Start
2016-02
Primary completion
2020-12-31
Completion
2020-12-31

Outcome

Outcome not reported

Stopped (Enrollment): “Terminate due to slow enrollment rate.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 100 mg Intranasal

Indications

No indication recorded.